HbA1c Laboratory Tests Market Growth Accelerates with 10.40% CAGR...

HbA1c Laboratory Tests Market Growth Accelerates with 10.40% CAGR Forecast

Veröffentlicht 2026-09-03 08:38:48

Market overview

The HbA1c Laboratory Tests Market is witnessing strong expansion as diabetes becomes an increasingly significant public health challenge worldwide. According to the latest analysis by Maximize Market Research, the market was valued at USD 2.12 billion in 2023 and is projected to reach USD 3.81 billion by 2030, growing at a CAGR of 10.40% during 2024–2030. HbA1c testing is increasingly important for diagnosing diabetes and monitoring long-term glycemic control because it reflects average blood glucose levels over approximately two to three months.

Market Estimation, Growth Drivers and Opportunities

The primary factor supporting the HbA1c Laboratory Tests Market is the rising global prevalence of Type 2 diabetes, fueled by aging populations, sedentary lifestyles, obesity and changing dietary patterns. As healthcare systems increasingly prioritize early diagnosis and continuous disease management, demand for reliable HbA1c testing is expanding across hospitals, diagnostic laboratories and primary-care settings. The increasing adoption of automated laboratory analyzers is another important growth driver because automation improves testing efficiency, throughput and consistency.

Technological progress is creating additional opportunities for manufacturers. Modern HbA1c systems increasingly emphasize faster turnaround times, improved analytical precision, automation, connectivity and point-of-care testing. The growing use of digital health platforms also creates opportunities to connect laboratory results with electronic health records and diabetes-management systems. However, high equipment, reagent, maintenance and skilled-labor costs remain significant barriers, particularly in low-resource markets.

U.S. Market Trends and Investment

The United States remains one of the most important markets because of its sophisticated healthcare infrastructure, high diabetes burden and strong adoption of advanced diagnostic technologies. During 2025, the broader U.S. diabetes diagnostics ecosystem attracted significant investment in faster and more accessible monitoring technologies. For example, Roche announced an investment of up to USD 550 million through 2030 to expand its Indianapolis diagnostics manufacturing hub for continuous glucose monitoring solutions, creating hundreds of jobs and strengthening U.S. production capabilities. Roche also highlighted portable multi-test point-of-care platforms and predictive continuous glucose monitoring among major diagnostic innovations emerging around 2025.Although this investment is primarily focused on CGM rather than HbA1c specifically, it demonstrates the broader direction of U.S. diabetes diagnostics toward decentralized, connected and technology-enabled monitoring. Abbott's Afinion 2 platform similarly supports near-patient cardiometabolic testing, providing HbA1c results in approximately three minutes.

Request To Free Sample of This Strategic Report ➤ https://www.maximizemarketresearch.com/request-sample/81466/

Market Segmentation – Largest Share

According to Maximize Market Research, the Immunoassay segment dominated the market by technology in 2023, supported by its accuracy, sensitivity, standardization, reliability and cost-effectiveness. Automation also enables immunoassay platforms to process high testing volumes efficiently. By Technology: Immunoassay – largest market share

By Testing Products: Kits – largest market share
By Region: North America – dominant regional market

The kits segment benefits from standardized reagents, defined testing protocols and reduced variability, while North America benefits from advanced healthcare infrastructure and strong diabetes-management programs.

Competitive Analysis

The global HbA1c testing industry remains fragmented, with several multinational diagnostics companies competing through automation, point-of-care systems, assay development and laboratory connectivity. A 2025 industry assessment identified Danaher, Roche, Siemens Healthineers, Abbott and Bio-Rad among the five leading competitors, with estimated market shares of approximately 6.5%, 2.4%, 2.2%, 1.5% and 1.4%, respectively, based on the broader HbA1c testing market.

Danaher Corporation: Through Beckman Coulter Diagnostics, Danaher continues to expand its diagnostics capabilities. At ADLM 2025, Danaher's diagnostics businesses emphasized an integrated approach covering diabetes and other diagnostic categories, alongside connected laboratory technologies. Danaher's 2025 innovations also included expansion of the Beckman Coulter DxI 9000 immunoassay platform menu, supporting its broader strategy of improving diagnostic speed and analytical performance.

Roche: Roche continues to invest heavily in diagnostic innovation and diabetes management. Its USD 550 million Indianapolis investment announced in 2025 strengthens U.S. manufacturing capabilities, while its Diagnostics division introduced 53 new tests and two instrument platforms in 2025.These investments support a wider ecosystem of automated laboratory testing, digital diagnostics and diabetes monitoring.

Siemens Healthineers: Siemens continues to strengthen rapid HbA1c testing through its Atellica DCA platform. The system delivers HbA1c results within minutes and integrates testing with point-of-care workflows. Siemens also announced a new strategic phase in 2025 emphasizing healthcare AI and addressing non-communicable diseases, including diagnostics innovation.

Abbott Laboratories: Abbott is expanding near-patient diagnostics through its Afinion 2 platform, which provides rapid HbA1c testing alongside other cardiometabolic tests. Its compact design and rapid results support testing within a single patient visit, strengthening opportunities for decentralized diabetes management.

Bio-Rad Laboratories: Bio-Rad remains an important participant through its HbA1c testing portfolio, including the VARIANT II TURBO system. Its automated solutions integrate HbA1c testing with laboratory workflows and are designed to improve efficiency, consistency and throughput. Bio-Rad's VARIANT II TURBO HbA1c systems have also received FDA clearances, supporting their use in clinical laboratory testing.

Regional Analysis

United States: The U.S. benefits from advanced laboratory infrastructure, high diagnostic adoption and substantial investment in diabetes care. Strong demand for early diagnosis and continuous monitoring supports HbA1c testing.

United Kingdom: The UK market is supported by national diabetes-management initiatives and the country's established healthcare system. Increasing emphasis on early diagnosis and prevention is expected to sustain testing demand.

Germany: Germany's advanced healthcare infrastructure and strong laboratory diagnostics sector create favorable conditions for automated HbA1c testing. European regulatory requirements also encourage manufacturers to maintain high standards of test performance and traceability.

France: France benefits from developed healthcare services and growing emphasis on chronic-disease management. Expansion of diagnostic capacity and preventive healthcare can support HbA1c testing adoption.

Japan: Japan's aging population and strong healthcare technology ecosystem provide long-term opportunities for diabetes screening and monitoring. Demand for accurate and efficient laboratory diagnostics is expected to increase alongside chronic disease management requirements.

China: China's large population, increasing diabetes burden and expanding healthcare infrastructure make it a significant growth opportunity. Government-led diabetes screening and public-health initiatives are supporting greater use of HbA1c testing.

Request To Free Sample of This Strategic Report ➤ https://www.maximizemarketresearch.com/request-sample/81466/

Key Players

Danaher Corporation
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Randox Laboratories Ltd.
Thermo Fisher Scientific Inc.
Sysmex Corporation
ARKRAY, Inc.
Tosoh Corporation

Conclusion

The global HbA1c Laboratory Tests Market is positioned for substantial growth through 2030, supported by the rising diabetes population, increasing awareness of early diagnosis and technological improvements in laboratory and point-of-care testing. The market's projected 10.40% CAGR demonstrates strong commercial potential.In our view, the greatest opportunities will come from rapid point-of-care systems, automated analyzers, standardized testing kits, digital connectivity and AI-enabled diabetes management. Reducing testing costs while expanding access in emerging economies could further accelerate adoption. As healthcare moves toward preventive, personalized and decentralized care, manufacturers that combine accuracy with speed, affordability and connectivity are likely to gain a competitive advantage.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.